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Introduction: The first-line therapy for the intermittent preventive treatment
of malaria in pregnancy (IPTp) is sulphadoxine--pyrimethamine (SP). There is
an urgent need to identify safe, well-tolerated and efficacious alternatives
to SP due to widespread Plasmodium falciparum resistance. Combination
therapy using azithromycin and chloroquine is one possibility that has dem-
onstrated adequate parasitological response > 95% in clinical trials of non-
pregnant adults in sub-Saharan Africa and where IPTp is a government policy
in 33 countries.
Areas covered: Key safety, tolerability and efficacy data are presented for
azithromycin and chloroquine, alone and/or in combination, when used to
prevent and/or treat P. falciparum, P. vivax, and several curable sexually trans-
mitted and reproductive tract infections (STI/RTI). Pharmacokinetic evidence
from pregnant women is also summarized for both compounds.
Expert opinion: The azithromycin--chloroquine regimen that has demon-
strated consistent efficacy in non-pregnant adults has been a 3-day course
containing daily doses of 1 g of azithromycin and 600 mg base of chloroquine.
The pharmacokinetic evidence of these compounds individually suggests that
dose adjustments may not be necessary when used in combination for treat-
ment efficacy against P. falciparum, P. vivax, as well as several curable STI/
RTI among pregnant women, although clinical confirmation will be necessary.
Mass trachoma-treatment campaigns have shown that azithromycin selects
for macrolide resistance in the pneumococcus, which reverses following the
completion of therapy. Most importantly, no evidence to date suggests that
azithromycin induces pneumococcal resistance to penicillin.
Keywords: antental care, azithromycin, chloroquine, fetal, intermittent preventive treatment,
malaria, maternal health, neonatal, pregnancy, reproductive tract infections, sexually transmitted
infections, sub-Saharan Africa
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1. Introduction
Malaria infection in pregnancy is associated with low birth weight [1], preterm deliv-
ery [2], intrauterine growth-retardation [3] and maternal anemia [4]. An estimated
125 million pregnant women worldwide are at risk of malaria infection each
year [5]. The World Health Organization (WHO) recommends the intermittent
preventive treatment of malaria in pregnancy (IPTp) for pregnant women in areas
of stable transmission [6] using a full-treatment course of 1.5 g sulphadoxine plus
10.1517/17425255.2011.598506 © 2011 Informa UK, Ltd. ISSN 1742-5255 1153
All rights reserved: reproduction in whole or in part not permitted
75 mg pyrimethamine (SP) administered two to three times
following the onset of fetal movement [6]. SP-IPTp is a gov-
ernment policy in 37 countries worldwide, 33 of which are
in sub-Saharan Africa [7]. The recent decline in parasite sensi-
tivity to SP makes identifying alternative therapies for use in
IPTp an urgent priority [8]. Table 1 lists the characteristics of
an optimal IPTp drug. While no candidates to replace SP
match the ideal profile, azithromycin--chloroquine (Box 1)
may be an attractive alternative for several reasons. Both
azithromycin [9-12] and chloroquine [13-16] have been safely
administered individually in all trimesters of pregnancy. The
combination has demonstrated additive to synergistic effect
in vitro [17] and in vivo [18] against Plasmodium falciparum.
Clinical trials in sub-Saharan Africa have produced day-
28 adequate parasitological responses (APRs) exceeding 95%
(studies 82563, 367653 [81] and 82576/O26-44 [83]) after
adjustment with polymerase chain reaction (PCR) methods,
a threshold recommended by the WHO for new and/or
Box 1. Drug summary.
Drug name (generic) Azithromycin-chloroquine
Phase Phase III
Indication Intermittent preventive treatment of malaria in pregnancy
Pharmacology description/mechanism
of action
Azithromycin is a slow-acting macrolide that targets the 70S ribosomal subunit of
the apical complex in susceptible microorganisms including malaria parasites
Chloroquine is a rapidly absorbed 4-aminoquinoline that accumulates in digestive
vacuoles, binds to hematin and prevents its expulsion from sensitive malaria
parasites
Route of administration Oral/Per os (PO)
Molecular formula Azithromycin -- C38H72N2O12
Chemical structure
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Chloroquine -- C18H26ClN3
NCI
NH
N
Pivotal trial(s) ClinicalTrials.gov Identifier: NCT01103063 ‘Evaluate Azithromycin Plus
Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent
Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In
Africa’ [113]
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alternative antimalarial therapy. A combination regimen
with the higher azithromycin dose of 2 g is required to
achieve > 95% parasitological clearance rates in India and
South America. If used in IPTp, azithromycin may also
provide protection against several sexually transmitted
and reproductive tract infections (STI/RTI) including
Treponema pallidum [19], Neisseria gonorrhoeae [20], Chlamydia
trachomatis [21], Trichomonas vaginalis [22], and possibly bacte-
rial vaginosis as observed with other broad-spectrum antibiot-
ics administered in the first half of pregnancy [23]. This could
be consequential as the combined prevalence of curable STI/
RTI is equal to, and higher in some settings, than the burden
of malaria in pregnancy among women who seek antenatal
care (ANC) in sub-Saharan Africa [24].
This review consolidates evidence from peer-review publi-
cations, conference reports and abstracts, as well as data
from a recently published Cochrane review of azithromycin
for the treatment of uncomplicated malaria in non-pregnant
adults and discusses the potential use of azithromycin plus
chloroquine for IPTp.
2. Leading candidates to replace SP in IPTp
2.1 Mefloquine
Excluding selected areas of multidrug resistance along the
Thai-Cambodian and Thai-Burmese borders, mefloquine is
an efficacious chemoprophylaxis for the prevention of
chloroquine-resistant P. falciparum [25] with a half-life between
14 and 41 days in healthy volunteers [26]. It is appealing as an
IPTp drug, in part, because it can be administered as a single
therapeutic dose, like SP, during ANC visits. Thus, policy
change from SP to mefloquine could have minimal impact
on ANC service delivery. However, the single-dose regimen
has been associated with a high prevalence of adverse reactions
among pregnant women in Malawi (750 mg) [27] and Benin
(15 mg/kg) [28]. In Benin, adverse events were experienced by
78% of women following the first mefloquine-IPTp dose, of
which 28% sought medical care for their side effects.
A review of mefloquine treatment among 3673 patients of all
ages living along the Thai-Burmese border found that the
most important adverse effect was drug-induced vomiting
within the first hour of ingestion [29]. Recently, a double-
blinded, placebo-controlled trial of racemic mefloquine and
(+)-mefloquine among healthy male and female volunteers in
the UK was terminated prematurely due to high frequency of
adverse events in both treatment groups. [30]. Severe central
nervous reactions are of particular concern, occurring in
~ 1 in every 6000 [31] to 10,000 [32] individuals. Women are
affected by these reactions two times more often than
men [33], a difference that may be attributable to dose-
related toxicity that is more common among individuals with
low body weight [34]. A Cochrane review of malaria chemopro-
phylaxis among travellers implicated mefloquine use at recom-
mended dosages in the deaths of 22 travelers, including five
suicides; no other drug had such reports [35]. Thus, despite its
P. falciparum efficacy and ease of single-dose administration,
it may be difficult to justify giving mefloquine to all women
in IPTp regardless of their malaria status. Providing
split-dose therapy may improve tolerability [36] but the long
half-life of mefloquine raises the potential for drug-induced
neuropsychiatric adverse events that persist for months [37].
2.2 Azithromycin-based combinations (other than
azithromycin plus chloroquine)
Sulphadoxine--pyrimethamine plus azithromycin may be useful
where there is a low-to-moderate prevalence of parasites with
dhfr/dhps (dihydrofolate reductase/dihydropteroate synthase)
mutations. However, evidence is inconclusive in locales with a
high prevalence of quintuple-mutant parasites. Recrudescent
malaria, for example, was less frequent in Malawi among preg-
nant women who received two courses of SP-IPTp plus azithro-
mycin (1 g/day for 2 days; 4 g total) compared with SP-IPTp
alone, but the prevalence of placental parasitemia was similar [38].
InMalawi, the APPLe study (Azithromycin for the Prevention
of Preterm Labor) failed to observe a difference in the prevalence
of preterm delivery and birth weight among pregnant women
who received 1 g azithromycin two times during the antenatal
period, along with SP-IPTp, when compared with SP-
IPTp alone [39]. One reason may have been the study design. In
both treatment groups, 7.1% of women were venereal disease
research laboratory VDRL-positive and, consequently, were
given 1 g benzyl penicillin; the WHO recommends 2.4 MU of
benzathine penicillin G (BPG) for pregnant women [40]. It is
unknown whether such a course of benzyl penicillin affects fetal
syphilis and, despite possibly curing maternal infection,
Table 1. Optimal IPTp drug profile.
The optimal IPTp therapy would be a combination of two
molecules that:
 Exhibit similar time above minimum inhibitory concentrations
 Support a once per month dosing regimen (£ 2 doses)
 Have different mode of actions to reduce resistance selection
 Are active against asexual & sexual stages
 Are not necessarily rapid acting*
 Are either a fixed dose or loose combination
 Different from first line treatment for symptomatic malaria
 Ideally active against other treatable maternal health
problems, e.g. STI/RTI, maternal-fetal transmission of infection
 Are safe during all the pregnancy, although pregnant women
are unlikely to receive the first dose of IPTp in the first
trimester
 Cost as little as possible per pregnancy with prices that are in
line with current price estimates for artemisinin combination
therapy (ACT)
Note: There are no new classes of medicines with plasma
exposures above MIC for 28 days. Such exposure is most likely
to be achieved by slow release depot formulations which would
require molecules with doses of less than 10 mg/day. No such
compounds currently exist.
*Symptomatic women are treated with ACTs.
Source: Duparc, S. (2011). Personal communication. Medicines for Malaria
Venture, Geneva, Switzerland.
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azithromycin has not been proven efficacious against congenital
infection if fetal tissues have already been penetrated by
T. pallidum [41]. Thus, inappropriate treatment for congenital
syphilis in both groups could have limited the protective effect
of azithromycin on preterm delivery.
In contrast to these findings, a trial in Malawi recently
reported clear benefit from more frequent dosing with
SP-IPTp and azithromycin. The incidence of preterm delivery
was 17.9 versus 15.4% among women given two doses of
SP-IPTp compared with women given monthly SP-
IPTp (p = 0.32). With the addition of 1 g azithromycin on
two occasions to monthly SP-IPTp, the incidence of preterm
delivery was lowered further to 11.8% (p = 0.01). In this
study, women who tested positive for syphilis were given
2.4 MU of BPG. Compared with the control group, women
who received azithromycin also had a 35% lower risk of
T. vaginalis infection (risk ratio = 0.65; p = 0.02) [22].
Piperaquine may possibly be combined with azithromycin
and may be better tolerated than chloroquine [42], although
the two have never been tested together and the teratogenicity
of piperaquine is unknown. Further investigation is needed
into the prolongation of the cardiac QTc interval observed
following piperaquine treatment [43]. Pyronaridine and
mefloquine have each demonstrated an additive effect in vitro
with azithromycin [17], although pyronaridine teratogenicity
requires evaluation. Dihydroartemisinin plus azithromycin
are additive to synergistic in vitro [44] whereas artesunate has
shown an antagonistic effect in vitro with azithromycin [17,45].
This is important as it may explain the poor in vivo efficacy
observed in Tanzania during a pediatric trial that combined
artesunate and azithromycin [46], but not seen in trials among
semi-immune adults in Thailand [47] and Bangladesh [48].
The in vitro antagonism between azithromycin and artesunate
may not have been apparent in Thailand and Bangladesh
because the semi-immune adults were better able to render
an acquired-immune response and, thus, overcame
infection despite the drug antagonism, compared with more
immunologically naive pediatric patients in Tanzania.
3. Introduction to the compounds
3.1 Azithromycin
3.1.1 Safety and tolerability
Synthesized in the 1980s, azithromycin is the first compound
of the azalide family of antibiotics. Animal studies have shown
that quantities two to four times the human daily dose do not
reduce fertility nor cause fetal harm [49]. Doses up to 2 g azi-
thromycin have been used in all trimesters of human preg-
nancy. A one-time dose of 1 g azithromycin is associated with
mild-to-moderate side effects in adults including diarrhea or
loose stools (7%), nausea (5%), vomiting (2%), and vaginitis
(2%) with < 1% experiencing dizziness, headache, vertigo
and/or somnolence [49]. Azithromycin is better tolerated
than erythromycin and can be taken for shorter time periods
to achieve the same therapeutic effect [50]. Long-term
azithromycin chemoprophylaxis amongHIV-positive patients,
however, may be poorly tolerated [51,52].
3.1.2 Efficacy
The chemoprophylactic efficacy of azithromycin against
P. vivax has been known for 15 years. A trial in Indonesia among
civilians and soldiers with limited immunity showed that a load-
ing dose of 750mg azithromycin, followed by 250mg/day, was
100% (95%CI: 83.9 -- 100) and 98.3% (95%CI: 89.4 -- 99.9)
protective, respectively, against P. vivax during a 20-week
period [53]. Comparable chemoprophylactic efficacy, 98%
(95% CI: 88 -- 100), was reported in a study among a similar
population in Thailand [54]. Although these studies were con-
ducted between 1996 and 1997, parasite sensitivity to azithro-
mycin is likely to be the same today as the drug has not been
used on any scale for malaria prevention.
Azithromycin is less active against P. falciparum. The trial
in Indonesia described above reported 88.4% (95% CI:
56.6 -- 97.4) and 62.9% (95% CI: 29.5 -- 80.4) protective
efficacy against P. falciparum in the same civilian and soldier
populations, respectively, over a 20-week period [53]. A study
of P. falciparum in India using a regimen of 1 g azithromycin
plus placebo chloroquine on days 0, 1 and 2 produced
an APR of 36% (5/14) at day 28 without PCR adjust-
ment [18]. This was the first part of a two-stage trial that
demonstrated in vivo synergy between azithromycin and
chloroquine, and is described in greater detail within the
azithromycin--chloroquine efficacy section.
3.2 Chloroquine
3.2.1 Safety and tolerability
Chloroquine is a 4-aminoquinoline antimalarial drug. Antena-
tal dosing with hydroxychloroquine throughout pregnancy has
shown to have no effect on newborns up to 1 year postpar-
tum [55]. An observational study did not detect any ophthalmo-
logical abnormalities in the children born to women who used
hydroxychloroquine or chloroquine for a mean of 7.2 months
during pregnancy [16]. The most commonly reported side effect
of chloroquine in African population is pruritus which peaks
24 h after an oral dose [56]. Tolerability may vary among African
populations as three times the treatment dose formerly recom-
mended by the WHO does not appear to increase the incidence
of adverse events in Guinea-Bissau [57]. Six times the therapeutic
dose of 600 mg chloroquine can produce hypotension and car-
diac failure [58]. Nevertheless, chloroquine is generally well toler-
ated in treatment doses, can be safely administered in any
trimester of pregnancy [13-16] and readily crosses the placenta
of pregnant women without teratogenic effect [59].
3.2.2 Efficacy
Chloroquine was developed in 1934 and became the first-
line treatment for all forms of malaria in the late 1940s and
1950s. A dose-finding study conducted during World War
II reported that a regimen of 1500 mg base was used over
3 days to cure 10 Chinese and 8 American soldiers infected
Azithromycin--chloroquine
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with P. falciparum along the India--Burma border [60], impor-
tant in so much as scant evidence was used to set a treatment
regimen that had only been slightly modified in WHO
recommendations some 50 years later [61]. A recent systema-
tic review of studies shows that chloroquine still has an
APR of 92.3% (95% CI: 90.3 -- 94.2) at day 28 against
P. vivax [62]. Treatment failures, however, have been on the
rise over the past 5 years [63] with the primary foci of resistance
in Indonesia, Papua New Guinea, Timor-Leste and other
parts of Oceania [64]. Reports of chloroquine resistance have
also come from India [65] and South America [66,67].
Although chloroquine remains available at the community
level in many settings, it is no longer recommended for the
treatment of uncomplicated P. falciparum infection. Prior to
the introduction of SP-IPTp, pregnant women commonly
received sachets of chloroquine chemoprophylaxis during ante-
ntal consultations, each containing four weekly doses of
300 mg for self-administration [68]. Even today, chloroquine
may offer modest chemoprophylactic effect against low birth
weight among pregnant women in West Africa [69], although
this may be limited to multigravidae [70]. Table 2 contains effi-
cacy data of four studies that included chloroquine monother-
apy arms, two being pediatric treatment trials of particular
note. These are described within their national contexts below.
3.2.2.1 Malawi and parasite sensitivity to chloroquine
Malawi was the first country in sub-Saharan Africa to abandon
chloroquine in favor of SP for the treatment of uncomplicated
malaria. In 1993, chloroquine treatment failure rates had been
as high as 57.8% [71]. Five years later, chloroquine in vitro test-
ing inhibited blood schizont development in 96.5% (28/29) of
isolates, suggesting that selection pressure for chloroquine-resis-
tant polymorphisms in the pfcrt and pfmdr1 genes reduced as
the use of chloroquine declined. Field sampling in 2001 failed
to detect parasites with pfcrt [72] and chloroquine in vivo was
100% efficacious (63/63) in eradicating P. falciparum from
asymptomatic semi-immune adults given 600 mg on days
0 and 1, and 300 mg on day 2 [73]. In 2005, a pediatric treat-
ment regimen of 10 mg of chloroquine base/kg on days
0 and 1, and 5 mg/kg on day 2 produced a 98.88% (79/80)
day 28 adequate clinical and parasitological response
(ACPR) [74]. Genetic analysis of P. falciparum isolates between
1992 and 2005 suggests that chloroquine-susceptible parasites
re-expanded their presence in Malawi after surviving unde-
tected within asymptomatic hosts at the time drug pressure
was removed [75]. Nevertheless, perpetuating chloroquine-
resistant polymorphisms comes with a high fitness cost for
P. falciparum [76], which remains the most likely explanation
for the rapid return of sensitivity.
3.2.2.2 Guinea-Bissau and the impotency of chloroquine
resistance
Plasmodium falciparum resistance to chloroquine was first
reported in Guinea-Bissau in 1990 [77]. Between 1992 and
2005, an estimated 33% of parasites (range 14 -- 54%) obtained
from asymptomatic children were chloroquine-resistant. Among
these strains, pfcrt 76T was associated with resistance but pfmdr1
86Y was not. In addition, the prevalence of single-nucleotide
polymorphisms at pfcrt positions 76, 271 and 326, and pfmdr1
position 86 did not change significantly [78]. During the same
time period in the same geographic areas, the median 3-day
chloroquine-treatment course was 63 mg/kg/day at health facili-
ties, ranging from 60 mg/kg in 1995 to 75 mg/kg in 2000.
Although the treatment efficacy was not reported, it appears as
though a regimen with 2.5 times the WHO-recommended
course suppressed the survival of P. falciparum and wild-type
mutation [79]. This suggests that chloroquine resistance, while
widespread, is not particularly potent [80].
Reinforcing this are data from a recent pediatric trial in
Guinea-Bissau. A 3-day course of 50 mg/kg chloroquine,
divided into six doses, was not inferior to a standard course
of artemether--lumefantrine (20 mg/120 mg) or Coartem,
(Novartis) administered as up to four tablets at 0, 8, 24, 36,
48 and 60 h. The day-28 PCR-adjusted ACPR was 95.1%
(150/158) for chloroquine and 96.6% (162/168) for arteme-
ther--lumefantrine. The PCR-adjusted ACPR for chloroquine
was 93.8% (138/148) at day 42 and 93.1% (114/125) at day
70 [82]. The PCR-adjusted ACPR among the 60 patients with
P. falciparum strains containing pfcrt 76T at days 28, 42 and
40 were 86.7, 82.3 and 79.7%, respectively [79]. No severe
drug-related adverse events were reported, although pruritus
was reported in 19.9% (36/181) of children in the chloro-
quine group compared with 5.4% among those given
artemether--lumefantrine (p < 0.001).
3.3 Azithromycin plus chloroquine
3.3.1 Safety and tolerability
Data available on the safety and tolerability of azithromycin
plus chloroquien are limited. However, the analysis in the
Cochrane review shows a dose--response relationship with azi-
thromycin and nausea; 33% (33/100) of participants given a
3-day course containing 2 g/day azithromycin reported nau-
sea, compared with 9.6% (11/114) from a 3-day regimen of
1 g/day azithromycin. No other dose--response relationships
were observed, although chloroquine-associated pruritus was
common in sub-Saharan Africa studies where the prevalence
ranged from 28.3% (32/113) to 51.8% (59/114) [81]. Data
are not disaggregated by country or study site, but as
previously noted, evidence from a study among children in
Guinea-Bissau suggests that some African populations tolerate
chloroquine better than others [79].
3.3.2 Efficacy
A placebo-controlled two-arm trial followed by an open-label
single-arm study in India demonstrated in vivo synergy using
the combination of azithromycin plus chloroquine [18]. In the
placebo-controlled trial, 32 semi-immune subjects were
treated for uncomplicated P. falciparum malaria with either:
(a) 1 g azithromycin plus chloroquine placebo for 3 days, or
Chico & Chandramohan
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(b) 600 mg chloroquine the first 2 days and 300 mg on the
last day, plus azithromycin placebo all 3 days. In the second
open-label study, 64 semi-immune subjects with P. falcipa-
rum infection were treated with azithromycin and chloro-
quine using doses similar to the two-arm trial. ACPR in
azithromycin without PCR correction at day 7 in the azithro-
mycin monotherapy arm was 62.5% (10/16) whereas in the
chloroquine monotherapy group it was 87.5% (14/16). By
day 28, azithromycin had continued to suppress fever and
parasites in only 33.3% (5/15) of subjects whereas chloro-
quine maintained an ACPR in just 26.7% of cases (4/15).
These outcomes were in contrast to the treatment effect
reported among subjects who received combination therapy.
ACPR at day 7 was 96.8% (61/63) and the same level
of ACPR was maintained at day 28. The observed difference
in ACPR between the two studies may have been exaggerated
because baseline parasite counts were three times higher
among subjects in the randomized trial compared with the
single-arm open-label study; mean parasite densities were
17,254 parasites/µl among those given azithromycin,
18,542 parasites/µl for chloroquine recipients, whereas the
azithromycin plus chloroquine group had a mean of 6417 par-
asites/µl. However, this baseline difference may not be conse-
quential in the context of IPTp; baseline mean parasite counts
in several recent studies of pregnant women across treatment
groups were 1154 per µl in Benin [28], 945 per µl in
Malawi [38] and 194 per µl in Ghana [82]. It is also likely
that women in sub-Saharan have greater acquired immunity
than their Indian counterparts. Thus, the synergy between azi-
thromycin and chloroquine observed in the Indian studies
may be replicable elsewhere among pregnant women whose
parasite densities at the time of treatment are equal to or lower
than levels reported in the Indian study population.
The results of several published clinical trials, conference
presentations and data from a recently published Cochrane
review are consolidated in Table 2, while important contextual
factors are discussed below. Studies investigating azithromycin
plus chloroquine involved only non-pregnant adults with
P. falciparum infections.
The first study of azithromycin plus chloroquine in sub-
Saharan Africa was a small two-arm placebo-controlled trial
in a high-transmission area of western Kenya that was sus-
pended prematurely due to logistical issues. Nevertheless, a
regimen of 1 g azithromycin plus 600 mg chloroquine daily
for 3 days was able to achieve parasite eradiation in five of
five subjects by day 28; one treatment failure (RIII) was
reported that cleared by day 7 and did not recur through day
28 [81]. This was followed up by a multicenter, multicountry,
placebo-controlled trial in sub-Saharan Africa that compared
two regimens of azithromycin (1 g vs. 500 mg) plus 600 mg
chloroquine daily on days 0, 1 and 2 against a split dose of mef-
loquine, 750 mg and then 500 mg 6 -- 10 h later, administered
on day 0. The study arm of 500 mg azithromycin was sus-
pended early based on the data from South America
and India; no data were reported. However the day-28
PCR-adjusted APR for the group given three doses of 1 g azi-
thromycin plus 600 mg chloroquine was 98.1% (101/103)
compared to mefloquine with 99.0% (102/103) [81]. Of
particular interest is the sub-analysis of APR by pfcrt prevalence
by the study site. In Ndola, Zambia, where the prevalence of
pfcrt was 27%, the APR at day 28 was 100% (55/55); in Jinja
and Kampala, Uganda, where pfcrt was 98%, the APR at day
28 was 94.4% (17/18) [83]. A confirmatory multicenter trial
comparing the same regimens of azithromycin--chloroquine
and mefloquine sans placebo showed that the day-28
PCR-adjusted APR for azithromycin--chloroquine was 100%
(107/107) and 99.1% (111/112) for mefloquine [81].
Several studies of azithromycin--chloroquine have been
conducted outside of sub-Saharan Africa and are included
in Table 2. Based on trials conducted in India, Indonesia
and Colombia/Surinam, regimens containing 500 mg azi-
thromycin plus 600 mg chloroquine for 3 days may contain
insufficient azithromycin to achieve 95% APR at day 28. Sim-
ilarly, regimens of 3 days containing < 600 mg chloroquine
each day (300 mg on day 2, for example) may also not be
able to reach the WHO-recommended treatment efficacy
threshold. A multicenter study in India and Colombia evalu-
ated a combination of 2 g azithromycin with 600 mg
chloroquine base once daily for 3 days; the PCR-adjusted
day-28 efficacy was 97.2% (104/107) [81,84].
4. Pharmacokinetics and pharmacodynamics
4.1 Azithromycin
Azithromycin is an analog of erythromycin, modified by the
insertion of a nitrogen atom into the macrolide nucleus. It is
stable at gastric pH with a high affinity for tissue due to the
presence of two basic tertiary amine groups which enhance
its amphiphilic properties [85]. Azithromycin targets the
70-S ribosomal subunit of the apical complex in susceptible
microorganisms including P. falciparum and P. vivax [86].
Once attached, azithromycin hinders polypeptide develop-
ment by triggering premature detachment and movement
along the peptide exit tunnel. Thus, azithromycin induces
‘delayed death’ by either inhibiting genetic translation and
causing the progeny of parasites to inherit non-functioning
apicoplast [86-89] or rendering second-generation parasites
incapable of establishing parasitophorous vacuoles following
erythrocytic invasion [86].
Azithromycin accumulates in hepatic, renal, pulmonary and
splenic tissue [90], slowly reaching the circulatory system over a
1-week period [86]. It has a half-life of 68 h in healthy volun-
teers [91] and an absolute bioavailability between 34 and 52%
following oral administration [92,93]. Less than 3.0% of a
maternal dose perfuses the placenta [94]. Azithromycin is not
known to cause any clinically significant interactions [95].
A study of 20 pregnant women showed that maternal
serum concentrations peak within 6 h of dosing and high
serum concentrations are sustained for 24 h [96]. Compared
with serum, azithromycin achieves high and sustained
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concentrations in the body tissues. In the above study, the
concentrations were seven, six and three times higher in pla-
cental, myometrial and adipose tissues, respectively. Figure 1
illustrates the concentration--time profile of azithromycin
over time in serum and tissues. A more recent pharmacoki-
netic study of azithromycin (two 2 g doses 24 h apart) plus
chloroquine (450 mg base daily for 3 days) given to
31 pregnant and 29 non-pregnant women in Papua New
Guinea showed that plasma concentrations of azithromycin
differ between groups within the first 48 h of dosing. The
pharmacokinetic profiles were similar between groups,
indicating that dose adjustments may not be necessary
among pregnant women, even in the presence of parasite-
mia [97]. Chloroquine pharmacokinetic end points were
not reported.
4.2 Chloroquine
Chloroquine is quickly absorbed and reaches high concentra-
tions in the digestive vacuoles of malaria parasites. Once there,
chloroquine forms a complex with ferriproporphyrin IX (FP),
a major toxic by-product of parasitic hemoglobin digestion,
preventing parasites from polymerizing FP into harmless
hemozoin and expelling it through their digestive vacuoles.
As a result, parasite membranes become highly permeable,
causing rapid death [98]. As discussed previously, resistance
to chloroquine is associated with parasite protein pfcrt
(mutant alleles K76T or, in two single cases, K76N or
K76I [99]). These are located in the digestive membrane of
the food vacuole [100,101]. Some researchers suspect that
pfcrt enables protonated chloroquine to escape the food
vacuole whereas others postulate that pfcrt binds directly to
chloroquine, inhibiting its ability to alter vacuole pH [102].
Peak plasma concentrations of chloroquine are reached
within 2 h of oral dosing with an absolute bioavailability rang-
ing from 70 to ~ 100% [103-105]. Chloroquine accumulates
extensively in hepatic, connective and pigmented tissues [106].
Greatest concentrations are found in erythrocytes, granulo-
cytes and platelets, whereas 55% is protein-bound in
plasma [106]. Its half-life is 1 -- 2 months [107,108].
Known pharmacokinetic interactions of chloroquine are
presented in Table 3. Of note, chloroquine reduces the
systemic exposure of praziquantel by 65% and peak concen-
trations by 59% [109]. Praziquantel is the first-line anti-
schistosomal therapy recommended by the WHO for use
among pregnant women in endemic areas [110].
A pharmacokinetic study in Thailand among 12 pregnant
and 13 non-pregnant women who received a 3-day course
of 25 mg/kg chloroquine for acute P. vivax malaria reported
that the total area under the whole-blood chloroquine concen-
tration--time curve tended to decrease with gestational age.
However, pregnancy did not alter overall pharmacokinetics
and researchers concluded that no adjustment in regimen
would be required for pregnancy [111]. The results of another
pharmacokinetic study in Papua New Guinea involving
30 pregnant and 30 non-pregnant indicate otherwise. Women
were given a daily dose of 450 mg chloroquine base for 3 days
along with SP-IPTp per national policy. Chloroquine and
related metabolites were still present 42 days later, but plasma
concentrations were significantly lower in pregnant women.
This may explain treatment outcomes among those with
asymptomatic parasitemia at enrollment. In total, 43.3%
(26/60) had malaria infections: 20 P. falciparum, 4 P. vivax,
and 2 P. malariae. By day 28, P. vivax and P. malariae cases
were cured whereas recrudescent P. falciparum was found
among 5 of 13 pregnant women and 2 of 7 non-pregnant
women. Thus researchers suggested a dose of 600 mg/
day among pregnant women, particularly important where
P. falciparum is prevalent. Table 4 combines key pharmacoki-
netic results from the two Papua New Guinea studies, com-
paring selected end points for chloroquine [112] and
azithromycin [97]. A Phase III multicenter study in sub-
Saharan Africa is testing a fixed-dose combination of azithro-
mycin--chloroquine for use in IPTp. The regimen contains
27% more chloroquine (620 mg base daily for 3 days) per
course than the amount used in Papua New Guinea with
the addition of 1 g azithromycin daily for 3 days [113].
A separate clinical trial being conducted in parallel at the
same sites will evaluate the parasite clearance rates and phar-
macokinetics of the same fixed-dose combination regimen in
pregnant women with P. falciparum parasitemia [114].
4.3 Azithromycin plus chloroquine
Azithromycin and chloroquine do not exhibit any direct phar-
macokinetic interactions [115]. Chloroquine is known to delay
cardiac repolarization through inhibition of the potassium ion
channel [116], increasing the chances of prolonging the electro-
cardiogram QT interval, while azithromycin does not [117].
The assessment of electrical alternans in an anesthetized
guinea-pig showed that there is no additional risk of arrhythmia
when azithromycin and chloroquine are used in combination;
azithromycin may even be slightly protective of arrythmogenic
risk when administered with chloroquine [118].
Re-emerging chloroquine sensitivity has been reported where
its use has been suspended [73,119]. Given that azithromycin and
chloroquine target unique metabolic pathways in Plasmodia, it
is possible that the re-introduction of chloroquine with azithro-
mycin as a partner drug may prevent re-selection of parasites car-
rying the pfcrt mutation. This must be verified in appropriate
clinical trials and monitored with ongoing surveillance. Azithro-
mycin use against trachoma in mass-treatment campaigns has
induced transient resistance in the pneumococci [120]. A cluster-
randomized trial for trachoma control in Ethiopia reported that
four treatments of 1 g azithromycin over a 1-year period among
children aged 1 -- 5 years of age increased the prevalence of azi-
thromycin resistance in pneumococcal isolates from 6.3%
(95% CI: 1.0 -- 15.7) to 62.3% (95% CI: 49.1 -- 75.4), a full
year after the final course of azithromycin has been adminis-
tered [121]. Communities were not followed after treatments
were stopped, but single-dose mass administration campaigns
have reported rapid increases in azithromycin resistance among
Azithromycin--chloroquine
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pneumococcal isolates, only to have them return to baseline levels
within 6 -- 12 months [120,122]. Data from Ethiopia shows similar
effects on the pneumococci following mass dosing of children
with 1 g azithromycin every 6 months. After 3 years and six
courses of azithromycin, 76.8% (95% CI: 66.3 -- 85.1) of chil-
dren carried azithromycin-resistant pneumococci, levels dropped
rapidly following the cessation of dosing. Most importantly,
however, is that no evidence appears to associate azithromycin
use with the selection of penicillin resistance among the pneumo-
coccus. It is unknownwhether macrolide resistance will persist in
the context of IPTp. Monitoring of resistance markers will be
important if AZCQ is adopted for antenatal use. The dosing reg-
imen of AZCQ, containing 3 g azithromycin (1 g daily for
3 days), may possibly be counterselective and curb wild-type
pneumococci survival; evidence from a 10-year multinational
surveillance study shows that the treatment of respiratory tract
0
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Figure 1. Pharmacokinetic elimination of 1 g azithromycin through maternal serum and myometrial, adipose and placental
tissue (ng/ml/h).
Adapted from [96].
Table 3. Drug interactions with chloroquine.
Drug Type Interaction with chloroquine Clinical significance
Chlorpromazine Antipsychotics Chloroquine, SP and amodiaquine increase
serum concentrations of chlorpromazine
1.7 -- 4.3 times [131]
Unknown
Cimetidine Histamine h2-receptor
antagonist
Cimetidine increases serum concentration
of chloroquine prolonging its half-life 48% [132]
Unknown
Codeine Opiate Chloroquine inhibits CYP2D6 and may
theoretically interfere with bio-activation
of codeine to morphine [133]
Unknown
Cyclosporine Immunosuppressant Cyclosporine concentrations increase up to
4.3 times when used with chloroquine [134]
Cyclosporine dosages may need
to be reduced during concomitant
chloroquine use
Kaolin-Pectin Antidiarrhoeal Kaolin--Pectin reduces the area under the
plasma-chloroquine concentration--time
curve by ~ 30% [135]
Unknown
Methotrexate Antimetabolite
and antifolate
Methotrexate peak concentrations are
reduced 20% and its area under the
concentration--time curve is reduced
28% with concomitant chloroquine use [136]
Unknown
Praziquantel Anthelmintic Concomitant use of chloroquine reduces
concentration--time curve of praziquantel
65% and peak concentrations 59% [109]
WHO recommends inclusion of
pregnant women in deworming
campaigns with 40 mg/kg
praziquantel [110]
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infections to the point of bacterial eradication minimizes the
potential for selecting and maintaining resistant strains [123].
The potential for developing azithromycin resistance
in syphilis is possible as has been observed in high-income coun-
tries [124]. This is considerably less likely to occur in sub-Saharan
Africa if pregnant women with syphilis are simultaneously
given BPG along with azithromycin--chloroquine.
5. Regulatory affairs
The combination therapy azithromycin--chloroquine is not
currently registered for any indication, although Pfizer may
pursue an application for IPTp. SP and mefloquine are both
manufactured by Roche Pharmaceuticals which is not known
to be preparing a registration dossier for the use of either
antimalarial therapy in pregnancy.
6. Conclusion
Azithromycin--chloroquine is a potential alternative to SP, hav-
ing shown efficacy against P. falciparum among non-
pregnant adults in sub-Saharan Africa, Colombia and India,
even in the presence of parasite populations saturated with
chloroquine-resistance markers. The combination may be safely
administered any time in pregnancy and offers benefits of clear-
ing several STI/RTI. Pharmacokinetic measurements in preg-
nancy suggest that dose adjustments may not be necessary for
azithromycin but daily chloroquine dosing needs to be 600 mg
for 3 days.
7. Expert opinion
Malaria transmission has declined in some epidemiological set-
tings. There is no evidence to suggest, however, that the risk of
malaria in pregnancy without preventive measures has declined
in the same locations. It is possible that the risk of adverse
events associated with malaria in pregnancy will increase for
an unknown period of time while malaria control and elimina-
tion measures are scaled up and multigravidae fail to acquire
immunity through exposure in earlier pregnancies. Thus, the
need to identify a replacement for SP is as important as ever.
Therapy that combines antimalarial and antimicrobial
protection, and safe administration in any trimester of
pregnancy, is essential to the profiles of drugs that may
replace SP for IPTp. This is important for three reasons:
i) the prevalence of malaria and curable STI/RTI in preg-
nancy is similar and the burden of STI/RTI will increase,
proportionately, as malaria control measures and elimina-
tion measures are scaled up; ii) peripheral parasitemia is
actually highest between gestational weeks 9 and 16, a
period when SP and all other compounds currently under
investigation, except azithromycin--chloroquine, would be
largely contraindicated [1,125]; and iii) T. vaginalis and the
bacteria associated with bacterial vaginosis are believed
to trigger preterm delivery by slowly secreting proteases
that degrade and weaken fetal membranes [126,127].
Subanalysis in a Cochrane review illustrates the importance
of early intervention: in five trials of 2387 women
who were treated before 20 weeks gestation, the use of
Table 4. Chloroquine pharmacokinetics and azithromycin pharmacokinetics among pregnant and non-
pregnant women in Papua New Guinea.
Chloroquine pharmacokinetic study* [112] Azithromycin pharmacokinetic study‡ [97]
Pregnant women
(n = 30) [95% CI]
Non-pregnant
women (n = 30)
[95% CI]
p Pregnant women
(n = 31) [95% CI]
Non-pregnant
women (n = 29)
[95% CI]
p
Parameter
CL/F (l/h) 32.0 [28.8 -- 36.5] 23.9 [21.3 -- 26.3] < 0.001
CLM/F (l/h) 5.74 [5.17 -- 6.55] 4.29 [3.82 -- 4.72] < 0.001
Vc/F (l) 3406 [2819 -- 4919] 2702 [2230 -- 3535] 0.007 647 [422 -- 995] 249 [157 -- 363] NS
VP2/F (l) 3888 [3708 -- 4104] 3672 [3456 -- 3888] 0.034
Vss/F (l) 7147 [6721 -- 9638] 6707 [5843 -- 7158] 0.009 8355 [7460 -- 8973] 6875 [6115 -- 7526] 0.002
t1/2a (h) 0.88 [0.57 -- 1.36] 0.39 [0.24 -- 0.56] < 0.001
t1/2b (h) 266 [244 -- 280] 291 [272 -- 313] < 0.001 20.7 [18.3 -- 22.8] 18.8 [15.3 -- 21] NS
t1/2g (h) 78.2 [74 -- 82.5] 77.1 [71.5 -- 84.5] NS
AUC0 -- ¥ 35,750 (mg · h/litre)
[31,343 -- 39,729]
47,892 (mg · h/litre)
[43,486 -- 53,746]
< 0.001 28,713 (µg h litre-1)
[25,913 -- 32,942]
31,781 (µg h litre-1)
[28,736 -- 38,012]
NS
*Chloroquine pharmacokinetic study: all women received 450 mg base chloroquine for 3 days plus SP-IPTp.
zAzithromycin pharmacokinetic study: women received either two 2 g doses azithromycin plus 450 mg base chloroquine for 3 days OR two 2 g doses
azithromycin plus SP-IPTp.
AUC0 -- ¥: Area under the curve; CL/F: Clearance from the first compartment/bioavailability; CLM/F: Metabolic clearance/bioavailability; NS: Not significant;
t1/2a: First distribution half-life; t1/2b: Elimination half-life; t1/2g: Terminal half-life; Vc/F: Volume of distribution of the first compartment/bioavailability; VP2/F: Volume
of distribution of the second compartment/bioavailability; Vss/F: Volume of distribution at steady state/bioavailability.
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antibiotics was associated with a statistically significant
decreased risk of preterm birth < 37 weeks (Peto Odds
Ratio 0.72, 95% CI: 0.55 -- 0.95) [23]. These encouraging
observations need to be verified by further clinical
study as the pooled data did not include head to head
comparisons of early versus late treatment. Nevertheless,
because azithromycin--chloroquine is safe in all trimesters,
healthcare providers may be less concerned about imprecise
gestational estimates in pregnancy while administering
this combination of drugs as IPTp. Treatment compliance,
however, will rely on pregnant women self-administering
drugs. Co-formulated tablets being tested for IPTp are
film-coated and, thus, may not have a bitter taste;
sugar-coating chloroquine tablets increased the use of
monotherapy by 64% [128] and could be considered
for azithromycin--chloroquine.
There is some concern that the use of azithromycin--chlor-
oquine in IPTp may increase the prevalence of azithromycin-
and erythromycin-resistant pneumococci, although evidence
from mass trachoma-treatment campaigns suggests that the
selection for resistant mutations is transient in non-
pregnant participants. This needs to be monitored as part of
any IPTp program.
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